-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Chia Tai Tianqing Pharmaceutical Group announced the launch of an "evaluation of TQB2450 injection combined with platinum-containing chemotherapy followed by sequential TQB2450 injection combined with anlotinib hydrochloride capsules versus tislelizumab injection combined with platinum-containing chemotherapy as the first-line treatment A randomized, open-label, parallel-controlled, multi-center phase III clinical trial on the effectiveness and safety of advanced non-squamous non-small cell lung cancer"
Prior to this, Chia Tai Tianqing has launched the first-line phase 3 of lung cancer compared with K drug: TQB2450 injection combined with Anlotinib hydrochloride capsules compared with pembrolizumab injection in the first-line treatment of advanced non-small cell lung cancer.